ReviewJournal of clinical medicine2020
Human Wharton's Jelly-Cellular Specificity, Stemness Potency, Animal Models, and Current Application in Human Clinical Trials.
Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Harnessing the Bio-Instructive Placental Extracellular Matrix: Structural Properties, Decellularization, and Applications in Regenerative Medicine.International journal of molecular sciences · 2026Review
- Hippo Pathway Regulation and Microenvironmental Cues Governing Human MSC Transition to Cancer-Associated Fibroblasts.Journal of cellular physiology · 2026Article
- From Biological Waste to Therapeutic Resources: A Comprehensive Review of Stem Cell Sources, Characterization, and Biomedical Potentials.Stem cell reviews and reports · 2026Review
- Article
- High-throughput quantification of osteogenesis in WJ-MSCs using Alizarin Red S, von Kossa, and Picro-Sirius red.Future science OA · 2025Article
- The Pathophysiology of Wharton's Jelly and Its Impact on Fetal and Neonatal Outcomes: A Comprehensive Literature Review.Medical sciences (Basel, Switzerland) · 2025Review
- Enhancing adipogenesis in Wharton's jelly multipotent mesenchymal stromal cells through lipidomic insights and fatty acid supplementation.Scientific reports · 2025Article
- Harnessing the Anti-Inflammatory Effects of Perinatal Tissue Derived Therapies for the Treatment of Inflammatory Skin Diseases: A Comprehensive Review.Stem cell reviews and reports · 2025Review
- Perspectives on the use of decellularized/devitalized and lyophilized human perinatal tissues for bone repair: Advantages and remaining challenges.Materials today. Bio · 2025Article
- Review
- The order of green and red LEDs irradiation affects the neural differentiation of human umbilical cord matrix-derived mesenchymal cells.Scientific reports · 2024Article
- Simulated lunar microgravity transiently arrests growth and induces osteocyte-chondrocyte lineage differentiation in human Wharton's jelly stem cells.NPJ microgravity · 2024Article
- A GMP-compliant manufacturing method for Wharton's jelly-derived mesenchymal stromal cells.Stem cell research & therapy · 2024Article
- Wharton's jelly and osteoarthritis of the knee.British medical bulletin · 2024Review
- Therapeutic role of extracellular vesicles from human umbilical cord mesenchymal stem cells and their wide therapeutic implications in inflammatory bowel disease and other inflammatory disorder.Frontiers in medicine · 2024Review
- In Vitro Simulated Neuronal Environmental Conditions Qualify Umbilical Cord Derived Highly Potent Stem Cells for Neuronal Differentiation.Stem cell reviews and reports · 2023Article
- Human Wharton's Jelly Mesenchymal Stem Cell Secretome Modifies the Processes of Neuroprotection and Epithelial-Mesenchymal Transition in Retinal Pigment Epithelium at Transcriptional Level.Molecular biology reports · 2023Article
- Human Mesenchymal Stromal Cells Derived from Perinatal Tissues: Sources, Characteristics and Isolation Methods.The Malaysian journal of medical sciences : MJMS · 2023Review
- Article
- Perinatal Stem Cell Therapy to Treat Type 1 Diabetes Mellitus: A Never-Say-Die Story of Differentiation and Immunomodulation.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Stem cell therapies offer a great promise for regenerative and reconstructive medicine, due to their self-renewal and differentiation capacity. Although embryonic stem cells are pluripotent, their utilization involves embryo destruction and is ethically controversial. Therefore, adult tissues that have emerged as an alternative source of stem cells and perinatal tissues, such as the umbilical cord, appear to be particularly attractive. Wharton's jelly, a gelatinous connective tissue contained in the umbilical cord, is abundant in mesenchymal stem cells (MSCs) that express CD105, CD73, CD90, Oct-4, Sox-2, and Nanog among others, and have the ability to differentiate into osteogenic, adipogenic, chondrogenic, and other lineages. Moreover, Wharton's jelly-derived MSCs (WJ-MSCs) do not express MHC-II and exhibit immunomodulatory properties, which makes them a good alternative for allogeneic and xenogeneic transplantations in cellular therapies. Therefore, umbilical cord, especially Wharton's jelly, is a promising source of mesenchymal stem cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.